Correlation of activated clotting time (ACT) with rFVLLa infusion and clinical efficacy in a patient with Glanzmann thrombasthenia and platelet alloantibodies.
Ameri
Afshin
A
Stolte
Scott
S
D016824:Antigens, Human Platelet / Q000276:immunology; D001777:Blood Coagulation / Q000187:drug effects*; D002648:Child; D000075202:Contraindications; D015942:Factor VIIa / Q000008:administration & dosage*; D006801:Humans; D007518:Isoantibodies / Q000097:blood; D017713:Platelet Transfusion / Q000009:adverse effects; D011994:Recombinant Proteins; D013915:Thrombasthenia / Q000097:blood / Q000188:drug therapy* / Q000628:therapy; D014914:Whole Blood Coagulation Time
D016824:Antigens, Human Platelet; D007518:Isoantibodies; D011994:Recombinant Proteins; D015942:Factor VIIa